Cargando…
Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation
Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our re...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168350/ https://www.ncbi.nlm.nih.gov/pubmed/37162961 http://dx.doi.org/10.1101/2023.04.25.538327 |
_version_ | 1785038839454105600 |
---|---|
author | Tse, A Janilkarn-Urena, I Lin, J Chang, X Efthymiou, C Idrissova, A Zhang, M Williams, CK Magaki, S Vinters, HV Davies, DL Gonen, T Gukasyan, HJ Seidler, PM |
author_facet | Tse, A Janilkarn-Urena, I Lin, J Chang, X Efthymiou, C Idrissova, A Zhang, M Williams, CK Magaki, S Vinters, HV Davies, DL Gonen, T Gukasyan, HJ Seidler, PM |
author_sort | Tse, A |
collection | PubMed |
description | Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our research shows DHM becomes ionized at near-neutral pH allowing formulation of salts with transformed solubility. The MicroED co-crystal structure with trolamine reveals DHM salts as metastable solids with unlocked hydrogen bonding and a thermodynamic bent to solubilize in water. All salt formulations show better inhibitory activity against AD tau than the non-salt form, with efficacies correlating to enhanced solubilities. These results underscore the role of structural chemistry in guiding selection of solubilizing agents for chemical formulation. We propose DHM salts are appropriate formulations for research as dietary supplements to promote healthy aging by combating protein misfolding. Additionally, DHM is a suitable lead for medicinal chemistry and possible development of CNS pharmaceuticals. |
format | Online Article Text |
id | pubmed-10168350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-101683502023-05-10 Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation Tse, A Janilkarn-Urena, I Lin, J Chang, X Efthymiou, C Idrissova, A Zhang, M Williams, CK Magaki, S Vinters, HV Davies, DL Gonen, T Gukasyan, HJ Seidler, PM bioRxiv Article Natural products are ligands and potential inhibitors of Alzheimer’s disease (AD) tau. Dihydromyricetin (DHM) is a CNS active natural product. Despite having signature polyphenolic character, DHM is ostensibly hydrophobic owing to intermolecular hydrogen bonds that shield hydrophilic phenols. Our research shows DHM becomes ionized at near-neutral pH allowing formulation of salts with transformed solubility. The MicroED co-crystal structure with trolamine reveals DHM salts as metastable solids with unlocked hydrogen bonding and a thermodynamic bent to solubilize in water. All salt formulations show better inhibitory activity against AD tau than the non-salt form, with efficacies correlating to enhanced solubilities. These results underscore the role of structural chemistry in guiding selection of solubilizing agents for chemical formulation. We propose DHM salts are appropriate formulations for research as dietary supplements to promote healthy aging by combating protein misfolding. Additionally, DHM is a suitable lead for medicinal chemistry and possible development of CNS pharmaceuticals. Cold Spring Harbor Laboratory 2023-04-28 /pmc/articles/PMC10168350/ /pubmed/37162961 http://dx.doi.org/10.1101/2023.04.25.538327 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Tse, A Janilkarn-Urena, I Lin, J Chang, X Efthymiou, C Idrissova, A Zhang, M Williams, CK Magaki, S Vinters, HV Davies, DL Gonen, T Gukasyan, HJ Seidler, PM Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title | Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title_full | Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title_fullStr | Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title_full_unstemmed | Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title_short | Improving the solubility of pseudo-hydrophobic Alzheimer’s Disease medicinal chemicals through co-crystal formulation |
title_sort | improving the solubility of pseudo-hydrophobic alzheimer’s disease medicinal chemicals through co-crystal formulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168350/ https://www.ncbi.nlm.nih.gov/pubmed/37162961 http://dx.doi.org/10.1101/2023.04.25.538327 |
work_keys_str_mv | AT tsea improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT janilkarnurenai improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT linj improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT changx improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT efthymiouc improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT idrissovaa improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT zhangm improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT williamsck improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT magakis improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT vintershv improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT daviesdl improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT gonent improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT gukasyanhj improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation AT seidlerpm improvingthesolubilityofpseudohydrophobicalzheimersdiseasemedicinalchemicalsthroughcocrystalformulation |